top of page
Anchor 1
Fri May 29 2026
LIFE SCIENCES | BUSINESS | MEDICINE | HEALTHCARE
Search


The FDA's Flexibility Problem: When Rigor Becomes Risk
Balancing Regulatory Standards with the Need for Rare Disease Innovation
Apr 28


Supreme Court Reverses Trump's Tariffs, Crushes Trade Policy
Why the Supreme Court’s latest decision changes the biopharma playbook, affects global supply chains, and questions Trump's executive leverage.
Feb 26


FDA’s Approvals in 2025 Favored Follow-Ons Over Breakthroughs
A closer look reveals how the new administration is dismantling the traditional biopharma roadmap.
Feb 18


Why TrumpRx Relies on Negotiation Rather Than Reform
The most significant structural shift in the history of American drug distribution just moved from "policy debate" to "live URL."
Feb 16


The Biopolitics of Deleting Chromosome 21
As we transition from editing genes to engineering chromosomes, the biopharma industry must confront a foundational question: Is our goal to cure suffering, or to curate the human species?
Jan 29


The Biotech CEO's Guide to Managing Trump
As we navigate the opening weeks of 2026, the biotech sector finds itself in a paradox: valuations are surging, M&A is rebounding toward a projected $200 billion year, and yet the very foundations of the industry’s scientific and capital models are being re-engineered by executive decree. For many discerning businesses, the mandate has shifted from managing risk to managing whim.
Jan 15
HEALTHCARE INSIGHTS
NEW YORK

bottom of page